Prurigo nodularis (PN), a chronic inflammatory skin disease associated with severe pruritus and substantial impairment in quality of life, has limited effective treatment options despite significant disease burden. To address this unmet need, a study evaluated the efficacy and safety of vixarelimab, a novel monoclonal antibody targeting key inflammatory and itch pathways, involving 443 participants with moderate to severe PN.
The study found that vixarelimab led to significantly greater reductions in itch severity compared with placebo, as measured by the Worst Itch Numeric Rating Scale (WI-NRS), with mean reductions of 56.2%, 51.0%, and 33.0% in the high-, mid-, and low-dose groups, respectively, versus 14.5% with placebo. Clinically meaningful improvement (≥4-point reduction on the WI-NRS) was achieved by 66.0%, 61.7%, and 29.8% of patients receiving high-, mid-, and low-dose…
